retinopathy glp 1 Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling GLP-1 receptor agonists are transforming

22 HerrmannJ.NathinD.LeeS

Nrf2 staining and translocation For visualization and quantification of endogenous Nrf2 translocation into the nucleus, glass 96-well plates were coated with fibronectin (1 g/ml) (Sigma) and poly-l-ornithine (40 g/ml) over night

doi:10.3389/fphar.2025.1613610 47

This includes those who: Have heart disease, kidney problems, or overweight Want to avoid weight gain or low blood sugar from other diabetes medicines People with overweight or obesity, including: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher and at least one weight-related health problem (such as high blood pressure or sleep apnea) Adults who have not met weight-loss goals with lifestyle changes alone Adolescents with obesity who qualify for certain GLP-1 medications Who should not receive GLP-1 medications